Media coverage about Masimo Corporation (NASDAQ:MASI) has trended somewhat positive on Thursday, Accern reports. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Masimo Corporation earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned headlines about the medical equipment provider an impact score of 46.4277274654338 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Oxygen Therapy Device Market 8% CAGR Expected To Grow by 2023 (medgadget.com)
- Oxygen therapy device market analysis and forecasts till 2023 explored in latest research (whatech.com)
- Masimo Corporation (MASI) Given Average Rating of “Hold” by Brokerages (americanbankingnews.com)
- Masimo Corp. (MASI) Reports FDA Clearance and Full Market Release of Rad-97 Pulse CO-Oximeter (streetinsider.com)
- Masimo : Announces FDA Clearance and Full Market Release of Rad-97™ Pulse CO-Oximeter® (4-traders.com)
MASI has been the subject of several recent research reports. Roth Capital increased their price objective on Masimo Corporation from $96.00 to $105.00 and gave the company a “buy” rating in a research note on Wednesday, July 19th. Zacks Investment Research downgraded Masimo Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, July 4th. Stifel Nicolaus initiated coverage on Masimo Corporation in a research note on Monday, July 10th. They issued a “buy” rating and a $105.00 price objective for the company. BidaskClub raised Masimo Corporation from a “hold” rating to a “buy” rating in a research note on Wednesday, July 12th. Finally, BTIG Research raised Masimo Corporation from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Monday, August 14th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $95.00.
Masimo Corporation (NASDAQ MASI) opened at 85.77 on Thursday. Masimo Corporation has a 1-year low of $53.78 and a 1-year high of $104.71. The company has a 50-day moving average price of $85.78 and a 200 day moving average price of $90.95. The firm has a market capitalization of $4.45 billion, a P/E ratio of 14.06 and a beta of 0.84.
Masimo Corporation (NASDAQ:MASI) last issued its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.71 by $0.12. The firm had revenue of $192.90 million during the quarter, compared to analysts’ expectations of $189.03 million. Masimo Corporation had a return on equity of 23.45% and a net margin of 45.90%. Masimo Corporation’s revenue was up 11.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.57 earnings per share. Analysts expect that Masimo Corporation will post $2.80 earnings per share for the current fiscal year.
In other news, Director Sanford Fitch sold 14,000 shares of the business’s stock in a transaction on Thursday, June 29th. The stock was sold at an average price of $92.06, for a total value of $1,288,840.00. Following the completion of the transaction, the director now directly owns 90,249 shares of the company’s stock, valued at $8,308,322.94. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Anand Sampath sold 40,000 shares of the business’s stock in a transaction on Tuesday, July 11th. The stock was sold at an average price of $92.00, for a total value of $3,680,000.00. Following the completion of the transaction, the chief operating officer now directly owns 20,000 shares of the company’s stock, valued at $1,840,000. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 126,000 shares of company stock valued at $11,732,930. 16.60% of the stock is currently owned by insiders.
TRADEMARK VIOLATION NOTICE: This piece was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.chaffeybreeze.com/2017/09/21/masimo-corporation-masi-earning-somewhat-favorable-media-coverage-analysis-shows.html.
Masimo Corporation Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corporation and related companies with MarketBeat.com's FREE daily email newsletter.